Table 2.
Active immunotherapy clinical trials for pediatric and young adult AML.
| Study title | NCT number | Therapeutic intervention | Country |
|---|---|---|---|
| First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk- myelodysplasia (HR-MDS) | NCT05086315 | Drug: SAR443579 | USA, Australia, France, Netherlands |
| Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | NCT04835519 | Biological: chimeric antigen receptor T cell | China |
| CLL-1/CD33 Targeted LCAR- AMDR Cells in Patients with Relapsed or Refractory Acute Myeloid Leukemia | NCT05654779 | Biological: LCAR-AMDR Cells Product | China |
| Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia | NCT03971799 | Biological: CD33CART | USA |
| Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/ Refractory Acute Myeloid Leukemia | NCT05023707 | Biological: anti-FLT3 CAR-T | China |
| Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/ Refractory Acute Myeloid Leukemia (AML) | NCT04884984 | Biological: anti-CLL1 CART | China |
| CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04265963 | Biological: CD123 CAR-T cells | China |
| CD38-targeted Chimeric Antigen Receptor T Cell (CART) in Relapsed or Refractory Acute Myeloid Leukemia | NCT04351022 | Biological: CART-38 | China |
| Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia | NCT05266950 | Biological: CI-135 CAR-T cells | China |
| Safety and Efficacy of CD123- Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | NCT04272125 | Biological: CD123 CAR-T cells | China |
| PLAT-08: A Study Of SC- DARIC33 CAR T Cells in Pediatric and Young Adults with Relapsed or Refractory CD33+ AML | NCT05105152 | Biological: SC-DARIC33 | USA |
| CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT03896854 | Biological: CART-19 | China |
| NKG2D CAR-NK & relapsed/refractory AML | NCT05734898 | Biological: NKG2D CAR-NK | China |
| Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | NCT05519384 | Drug: JK500 cell injection | China |
| Optimized Dual CD33/CLL1 CAR T Cells in Subjects with Refractory or Relapsed Acute Myeloid Leukemia | NCT05248685 | Biological: Dual CD33/CLL1 CAR T | China |
| Multi-institutional Prospective Research of Expanded Multi- antigen Specifically Oriented Lymphocytes for the Treatment of Very High-Risk Hematopoietic Malignancies | NCT02203903 | Biological: tumor-associated antigen lymphocytes | USA |
Clinical trials found on http://www.clinicaltrials.gov as of 1 June 2023.